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Downregulation: reduction in the rate of transcription to a level below that
which would otherwise be observed. The opposite is termed upregulation.
Impairment of activation: prevention of or reduction in the activation of
transcription by other factors.
Inverse regulation: activation of transcription by nuclear receptors in the
absence of ligand, and downregulation in the presence of ligand.
Negatively regulated genes: genes that are downregulated under conditions
that would normally be expected to increase their rate of transcription.
Repression: reduction in the rate of transcription to a level lower than basal
through the recruitment of repressive factors or complexes.
Squelching: indirect interference in the transcription of a gene through theNuclear receptors are arguably the best understood
transcriptional regulators. We know a great deal about
the mechanisms through which they activate transcrip-
tion in response to ligand binding and about the
mechanisms through which they repress transcription
in the absence of ligand. However, endocrine regulation
often requires that ligand-bound receptors repress tran-
scription of a subset of genes. An understanding of the
mechanism for ligand-induced repression and how this
differs from activation has proven elusive. A number of
recent studies have directly or indirectly addressed this
problem. Yet it seems the more evidence that accumu-
lates, the more complex the mystery becomes.
Classical repression by unliganded nuclear receptors
The first insights into how nuclear receptors repress tran-
scription in the absence of their activating ligands were
obtained through cloning of the corepressor proteins si-
lencing mediator of retinoid and thyroid hormone receptor
(SMRT) [1] and nuclear receptor corepressor (NCoR) [2]
that interact withmany unliganded nuclear receptors. It is
now known that corepressor proteins exist as large multi-
protein complexes containing enzymes such as histone
deacetylases that repress transcription by regulating the
nature of the chromatin local to the gene promoter. Cor-
epressors are usually released on ligand binding through
changes in the conformation and dynamics of the receptor
ligand-binding domain, which favour recruitment of coac-
tivator proteins (Figure 1) [3]. An important feature of
these interactions is that corepressors and coactivators
bind to overlapping surfaces on the nuclear receptors such
that their binding is mutually exclusive. This is important
because competition between coregulator proteins can play
a key role in the tissue-specific regulation of some target
genes [4].
Although the classic activity of most ligand-bound nu-
clear receptors activates transcription, ligand-bound nu-
clear receptors repress the transcription of certain genes, a
process termed negative regulation. The classic example of
this is repression of thyroid-stimulating hormone (TSHa)
by the thyroid receptor (TR) in the presence of T3. It is now
known that such negative regulation occurs with many
other nuclear receptors and genes.
Over the years, various mechanisms have been sug-
gested to explain how ligand-dependent repression occursCorresponding author: Schwabe, J.W.R. (john.schwabe@leicester.ac.uk).
1043-2760  2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.tem.2010.11.004(Figure 1). Here we discuss these different mechanisms
and examine how they can be reconciled with recent
genome-wide studies.
Negative response elements
A relatively long-standing idea in the nuclear receptor field
is the concept of negative response elements. This concept
emerged when it became clear that ligand-bound glucocor-
ticoid (GR) and TR receptors downregulate specific target
genes, which raised the question as to what mechanism
might explain how ligands could have opposite transcrip-
tional effects on certain genes. Studies of GR downregula-
tion of the prolactin gene revealed that ligand-bound GR,
associated with a negative glucocorticoid response element
(nGRE), acts through the ‘reversal of a constitutive en-
hancer activity’ [5]. The authors speculated that when
ligand-bound GR binds to nGREs, its conformation does
‘not support’ transcriptional activation. However, the mo-
lecular mechanism underlying this phenomenon remained
uncertain.
Subsequent studies investigating downregulation of the
genes encoding TSHa [6] and TSHb [7] identified a nega-
tive thyroid hormone response element (nTRE) in the
proximal promoter, between the TATA box and the tran-
scriptional start site of the gene. It was proposed that
downregulation was the result of steric interference with
other components of the transcriptional machinery.
Intriguingly, examination of the DNA sequence of both
nGRE and nTRE suggested that the sequences are signifi-
cantly divergent from the classical positive response ele-
ments that mediate transcriptional activation by these
receptors, which brought into doubt whether or not recep-
tors actually bind to negative response elements. This
issue was resolved using a TRb mutant defective insequestering of factors normally required for its transcription. This can result in
down- or upregulation of the gene in question.
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Figure 1. Diverse modes of signalling by nuclear receptors. (a) Classical nuclear receptor (NR) signalling. (i) Transcriptional repression through recruitment of corepressor
complexes to unliganded nuclear receptors. (ii) Transcriptional activation through recruitment of coactivators to ligand-bound nuclear receptors. (b) Ligand-dependent
repression of transcription. (i) Negative response element: direct recruitment to DNA. (1) Nuclear receptor interference with the activation of transcription by other factors.
For example, ligand-bound TR prevents the general transcriptional activator SP1 from binding to the b-amyloid precursor gene. (2) Coactivator role reversal leading to
transcriptional repression. For example, SRC1 contributes to repression by ligand-bound TR. (3) Inverse recruitment of corepressors to ligand-bound receptors. For
example, the corepressor NCoR has been implicated in association with ligand-bound TR on the gene encoding TSHa. (4) Factors such as RIP140 act as inverse regulators
because they serve as corepressors yet are recruited to ligand-bound receptors. (5) Synthetic and natural inverse agonists serve as negative ligands because they promote
recruitment with corepressor complexes. For example, haem-binding promotes repression by REV-ERB. (ii) Trans-repression by ligand-bound receptors. (6) Ligand-bound
GR interacts with and prevents activation of AP1-mediated transcription. (7) Ligand-bound TR contributes to repression of the gene encoding TSHb through interaction with
the GATA2 transcription factor. (iii) Downregulation through off-DNA mechanisms. (8) Genome-wide studies suggest that many downregulated genes do not directly
recruit nuclear receptors. Hence, the downregulation observed is likely to be due to squelching effects.
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TSH genes in response to T3 in both cell-based assays [8]
and knock-in mice [9]. Thus, these findings demonstrated
that DNA-binding activity is necessary to downregulate
TSH genes.
Support for the idea that negative response elements
function through promoter interference mechanisms came88from further studies of the prolactin and b-amyloid pre-
cursor genes. It was shown that a GR binding site (nGRE)
in the prolactin promoter overlaps with the binding sites
for other transcription factors, including Oct-1 and Pbx.
Addition of an isolated GR DNA-binding domain to the
nuclear extract precluded DNA binding of both Oct-1 and
Pbx [10], which implies that direct competition exists for
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Figure 2. The conundrum of downregulation by ligand-bound nuclear receptors.
When ligand-bound nuclear receptors negatively regulate target genes, many of
the classical principles of nuclear receptor signalling are reversed.
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sites for TR and the transcription factor SP1 overlap each
other in the b-amyloid precursor protein (APP) promoter
[11]. T3 binding to TR increases the DNA-binding affinity
of TR, preventing SP1–DNA complex formation and con-
sequently downregulating SP1-dependent expression of
APP. Together, these findings suggest an interplay be-
tween competing transcriptional regulators on certain
promoters. Consequently, ligand-bound nuclear receptors
can block transcriptional activation by other factors, which
leads to downregulation of these genes.
Role reversal of coregulators
Since the early studies of negative response elements, we
have learnt that nuclear receptors (like most transcription
factors) regulate gene expression through the recruitment
of large complexes containing a variety of coregulators and
effector enzymes that target chromatin and other factors.
As discussed, in the classical activity of nuclear receptors,
ligand-bound receptors recruit coactivator complexes and
unliganded receptors bind corepressor complexes. This of
course raises the question as to what type of coregulator
complex is recruited by liganded receptors on a negatively
regulated promoter. This is a difficult problem because
multiple studies have explained how ligand binding to
nuclear receptors promotes interaction with coactivator
complexes containing histone acetylases (and methyl
transferases) and displaces corepressor complexes associ-
ated with histone deacetylases (and demethylases). So
what explains downregulation by ligand-bound receptors?
Do they somehow recruit corepressors on negatively regu-
lated genes? Or do histone acetylases somehow repress
these genes? This conundrum is illustrated by the cartoon
in Figure 2.
Anearly studyofnegative regulationof thegeneencoding
TSHa provided evidence that the role of coregulators might
be reversed on negatively regulated genes, because recruit-
ment of corepressors to the gene encoding TSHa was asso-
ciatedwithactivation [12].The reversal ofactionseemsto lie
in the finding that corepressor recruitment to this gene
results in histone acetylation. Similarly, the corepressor
SMRT mediates an increase in transcription at the nTRE
within theRous sarcomavirus long terminal repeat ofTSHa
[13]. In this case, protease digestion and mobility shift
assays suggested that the TR–SMRT complexes had differ-
ent conformationsdependingonwhether theywereboundto
a negative or positive hormone response element. Further
studies lend support to the concept of coregulator role
reversal depending on the particular response element.
TR mutants defective in corepressor recruitment no longer
activate an nTRE present in theSOD1 promoter. Converse-
ly, a receptor defective in coactivator recruitment, but still
able to interact with corepressors, shows impaired down-
regulation in response to thyroid hormone [14,15].
The role of coactivators in mediating repression is sup-
ported by several studies. Mice lacking the steroid receptor
coactivator-1 (SRC1) revealed a role for this coactivator in
activating some liganded TR-responsive genes and also
repressing transcription from liganded and unliganded
TR-responsive genes [16,17]. Similarly, the coactivator
SRC3 functions as a repressor in lymphocytes [18].Taken together, these findings suggest that both pro-
moter and cellular context can determine whether a par-
ticular coregulator acts as an activator or a repressor. Two
aspects of these role reversals remain unclear. First, what
is it about a particular promoter element or cellular envi-
ronment that results in coregulator role reversal? Second,
how are such role reversals implemented by the coregu-
lator complexes?
Evidence that the sequence of DNA response elements
can influence transcriptional outcome came from studies of
various GR binding sites that seem to require or exploit
different activation domains within the receptor [19]. In-
deed, a single base-pair change in the DNA of the response
element influences GR conformation [20]. Thus, it seems
that DNA serves as a sequence-specific allosteric ligand
that modulates the regulatory activity of the GR.
The histone demethylase LSD1 illustrates a well-estab-
lished example of the mechanism through which the role of
a coregulator can be reversed. LSD1 normally acts as a
corepressor when recruited to chromatin as part of the
CoREST complex. However, LSD1 can act as a coactivator
of the androgen receptor [21]. The mechanism for this
switch in activity has recently been established. When
acting as a corepressor, LSD1 demethylates lysine 4 on
histone 3 (H3K4). When histone 3 is phosphorylated
(H3T6) by PKCb kinase, which is recruited by the andro-
gen receptor, then LSD1 demethylates H3K9 and leaves89
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transcription [22]. This illustrates how a simple post-
translational modification can lead to reversal of transcrip-
tional activity.
It seems likely that covalent modifications, as well as
differential splicing of coregulators, will explain many
examples of coregulator role reversal. In addition to a large
repertoire of splice variants, coregulator proteins are ex-
tensively modified by acetylation, phosphorylation, ubiqui-
tination,methylation and SUMOylation [23–26]. Together,
these variations give enormous scope for fine-tuning of the
transcriptional outcome.
Inverse recruitment of corepressors
Role reversal of coregulators (e.g. a corepressor acting as a
coactivator) is now well established. However, it was re-
cently shown that another mechanism plays a role in
negative regulation. In this case, it seems that a ligand-
bound TR can repress genes by recruiting the corepressor
NCoR. This can be thought of as inverse recruitment of
coregulators. The evidence for this arises from a recent
study in mice containing a mutant corepressor, NCoR,
harbouring mutations in the deacetylase activation do-
main (DAD), which abrogate interaction with the deace-
tylase HDAC3. In these mice, several TH-responsive genes
are modestly activated in the absence of TH, which sug-
gests that failure to recruit HDAC3 leads to a failure of
normal gene repression. However, more surprisingly, sev-
eral genes that are normally repressed by ligand-bound TH
are activated in themutantmice [27]. This suggests that on
positively regulated genes, NCoR is displaced on ligand
binding to the TR, which allows recruitment of coactiva-
tors, but on the negatively regulated TSHa promoter,
NCoR is recruited to the ligand-bound TR, which leads
to transcriptional repression. It remains to be understood
through what mechanism this inverse recruitment of cor-
epressors on negatively regulated genesmight be achieved.
Inverse coregulators recruited by normally activating
ligands
The concept of coregulator role reversal derives from the
finding that coregulators that normally bring about one
outcome, can in certain circumstances, bring about the
opposite outcome. At least one coregulator has been identi-
fied that seems to be the extreme example of role reversal.
Receptor interacting protein of 140 kDa (RIP140) is a cor-
egulator with multiple interaction motifs that allow it to be
recruited to ligand-bound receptor [28]. However, RIP140
acts as a corepressor protein that recruits histone deacety-
lase enzymes through several complexes [29]. Thus, RIP140
can be considered an inverse coregulator. Its biological role
seems to be regulation of metabolism by balancing the
activities of the conventional coactivator PGC1a [30]. Simi-
larly,LCoR isa corepressor that is recruited to ligand-bound
oestrogen receptor a (ERa). Like RIP140, LCoR recruits
other repressor molecules such as the C-terminal binding
protein and histone deacetylases [31].
Inverse agonists promote corepressor recruitment
Nuclear receptors are important targets for pharmaceutical
intervention and there has been much effort to develop90agonists to activate the receptor and antagonists to compete
with and block the activation activity of the natural ligand.
Importantly, a third type of synthetic ligand for nuclear
receptors has emerged, inverse agonists. These pharmaceu-
tical ligands bind to nuclear receptors and promote the
recruitment of corepressor complexes, which leads to active
repression of target gene transcription in response to
ligands. One example of an effective pharmacological in-
verse agonist is tamoxifen, which binds to the oestrogen
receptor, promotes recruitment of corepressors such as
NCoR, and represses oestrogen receptor target genes.
It has only been relatively recently recognized that
naturally occurring ligands can act as inverse agonists.
REV-ERBa and b were originally described as orphan
receptors that seemed to function as constitutive transcrip-
tional repressors, directly binding to DNA and recruiting
the NCoR corepressor [32]. The lack of activation was
explained by sequence analyses that suggested that they
lack the carboxy-terminal helix of the ligand-binding do-
main, which is essential for coactivator recruitment by
other nuclear receptors. Recent studies have revealed that
haem serves as a regulatory ligand for REV-ERB. Howev-
er, haembinding does not activate the receptor, but instead
increases the affinity for the NCoR corepressor, which in
turn enhances the repression activity [33].
Like REV-ERB, no regulatory ligand for RORb had been
identified. However, the crystal structure of RORb
revealed a fatty acid ligand (stearate) in the ligand-binding
pocket. Surprisingly, the steric acid ligand does not seem to
activate or antagonize RORb transcriptional activity [34].
More recently, however, it was found that RORb binds all-
trans retinoid acid, which downregulates the transcription-
al activity of RORb [35]. Thus, it seems that retinoic acid
might act as an inverse agonist of RORb.
Another receptor that seems to be regulated by a natu-
ral inverse agonist is the constitutive androstane receptor
(CAR), a xenobiotic-responsive transcription factor. This
receptor, as suggested by its name, has strong transcrip-
tional activity in the absence of ligand. This constitutive
activity is explained by some structural differences that
lock the receptor in an active conformation [36]. Some
years ago, it was shown that the androstane metabolite
(androstanol) acts as an inverse agonist and reverses the
constitutive activity of CAR [37]. The crystal structure of
CAR with androstenol shows that this inverse agonist
binds within the ligand-binding pocket and locks the re-
ceptor in an inactive conformation that does not support
coactivator binding, but instead allows the recruitment of
corepressors [38,39].
Indirect repression by ligand-bound nuclear receptors
Nuclear receptors often engage in crosstalk with other
transcriptional regulators, and in many cases this results
in repression of the activity of other factors. This is termed
trans-repression and is commonly dependent on ligand
binding to the nuclear receptor. One of the earliest exam-
ples of this involved an interaction between the ER and the
tissue-specific transcription factor Pit-1, which leads to
downregulation of the prolactin gene [40].
Later, using different in vivo strategies, a model was
proposed for such trans-repression by GR that involves
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scription factors such as NF-kB [41] and AP1 [42,43]. More
recently, it was demonstrated for AP1 transcription factors
that only dimers containing FOS are trans-repressed by
GR. Thus, the dimer composition of AP1 can regulate the
positive and negative transcriptional activity [44]. In this
type of trans-repression mechanism, it seems that the
nuclear receptor itself does not bind directly to DNA and
indeed in some cases the DBD is not needed for trans-
repression to occur [40,42]. However, in other cases the
nuclear receptor DBD does seem to be required, which
suggests that the DBD plays a role in the interaction with
other transcription factors [45–47].
Recent experiments on negative regulation of the gene
encoding TSHb suggest that crosstalk occurs between
ligand-bound TR and the transcription factor GATA2
[48]. The Zn-finger region of GATA2 interacts with the
TR DBD, and this complex is required for negative regula-
tion by thyroid hormone. In this case, the effect of the
ligand perhaps controls the differential affinity of TR for
the GATA2-RE and the negative regulatory element [49].
Another important example of trans-repression is me-
diated by PPARg. Ligand-dependent SUMOylation of the
PPARg ligand-binding domain results in PPARg recruit-
ment of the corepressor (NCoR)–histone deacetylase-3
(HDAC3) complex to inflammatory gene promoters [50].
Insights from genome-wide studies
Genome-wide studies of transcription have dramatically
changed our view of transcriptional repression by nuclear
receptors. Although we used to believe that downregula-
tion of genes in response to nuclear receptor ligands was a
relativelyminor affair, it turns out that asmany as half the
genes regulated by nuclear receptor ligands are in fact
downregulated [51]. Clearly in some cases this will be a
secondary effect of upregulation of another factor such as a
repressive transcription factor or even a corepressor pro-
tein. However, it seems that much of the downregulation
by nuclear receptor ligands occurs on the same time scale
as upregulation, which argues against secondary effects
being responsible for this downregulation. How can this
large-scale downregulation be explained?
Microarray-based gene-expression profiling experi-
ments have identified genes that are either up- or down-
regulated by nuclear receptors. Analysis of these
experiments together with ChIP-on-chip and ChIP-Seq
experiments revealed the location of the binding sites for
nuclear receptors. What has emerged from these studies is
that themajority of upregulated genes, both for the ER [52]
and GR [53], are associated with binding sites for the
receptor. In stark contrast, few of the downregulated genes
seem to be located in realistic proximity to binding sites for
the receptors. Thus, it seems that much of the downregula-
tion observed occurs without interaction between the nu-
clear receptor and a promoter or enhancer sequence close
to the regulated gene.
To explain this, we must give some thought to the
inherent transcriptional potential of the cell at any one
time. If we assume that there is a maximum amount of
transcription a cell can perform, perhaps through limited
concentrations of certain components of the transcriptionalmachinery, then a sudden upregulation of one set of genes
in response to an activating ligand will necessarily result
in downregulation of other genes. This phenomenon is well
known in the transcription field as squelching and is
commonly observed when a transcriptional regulator is
overexpressed [54]. The excess non-DNA-bound material
titrates out other components of the transcriptional ma-
chinery and hence causes downregulation of other genes
because the squelched components become limiting. If
squelching is really the explanation for this large-scale
downregulation of gene expression in response to activat-
ing nuclear receptor ligands, we must ask whether this
downregulation is physiologically important.
A recent puzzle has emerged through mapping of the
genome-wide locations of histone acetyltransferases
(HATs) and HDACs. These genome-wide studies revealed
that not only are HATs associated with actively tran-
scribed genes, but HDACs (well-known components of
repression complexes) are also found almost exclusively
at active genes [55]. This suggests that we need to
completely reconsider the roles of the coregulators. One
explanation, of course, is that active genes are associated
with acetylated histones. Acetylated histones are sub-
strates for HDACs, so perhaps it is natural that HDACs
should be at active genes. Indeed, a study examining ERa-
induced expression of the gene encoding PS2 revealed that
transcriptional activation is a cyclical process in which
recruitment of ERa and proteins involved in activation
and repression cycle approximately every 40 min [56].
Acetylation, deacetylation, methylation and demethyla-
tion of histones H3 and H4 also followed a cyclical pattern.
These findings suggest that corepressor recruitment might
be an essential part of transcriptional activation by serving
to reset the transcriptional machinery.
Perspectives
Over the last 25 years of studies of transcription regulation
by nuclear receptors, many overarching general principles
have emerged that have stood the test of time. These
include the concepts of: (i) DNA response element recruit-
ment of receptors to promoters or enhancers of target
genes; (ii) binding of ligands to nuclear receptors to control
the recruitment of coregulator complexes; and (iii) imple-
mentation by coregulator complexes containing histone-
modifying enzymes of a histone code that directs transcrip-
tional activity of target genes by modifying the structure of
chromatin. However, as the details have been explored, it
has emerged that each of these broad concepts encom-
passes an enormous range of diversity with multifunction-
al complexes and outcomes. At one time, downregulation of
genes in response to nuclear receptor ligands seemed to
conflict directly with the established principles. Now, set in
the context of the widely diverse details of gene regulation,
this downregulation no longer seems so surprising, nor
should it be unexpected that many different mechanisms
contribute to this ligand-dependent downregulation.
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